ClinicalTrials.gg
CompletedNCT05303402Updated Nov 17, 2026

A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.

A Phase 2/3 interventional study of PHH-1V in SARS CoV 2 Infection, sponsored by Hipra Scientific, S.L.U. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hipra Scientific, S.L.U · Phase 2/3, Interventional, and Prevention

How we know

Updated Nov 17, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.

Enrollment
94th of 254
240 · median 132
Started
2022
with 47 others
Phase 2/3
25 of 401
1 open now
Registered
310th of 401
by date
Lead sponsor
7 of 401
Hipra Scientific, S.L.U

Among the 401 studies in COVID-19 with a site in Spain, this one is the 94th largest by enrollment of the 254 interventional ones that give a count, is one of 48 that started in 2022, is one of 25 in phase 2/3, and was the 310th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in COVID-19 with a site in Spain, or all of them as a file.
02

Study summary

A phase IIb/III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in adults with pre-existing immunosuppressive conditions vaccinated against COVID-19

Read the detailed description

This is a phase IIb/III, open label, single arm, multi-center clinical trial that aims to determine safety, reactogenicity, tolerability and immunogenicity of additional vaccination with a recombinant protein receptor binding domain (RBD) fusion heterodimer candidate against SARS-CoV-2 developed by HIPRA (PHH-1V) in individuals with pre-existing immunosuppressive conditions. In this phase III study, approximately 400 eligible individuals who have received primary vaccination against COVID-19 with 3 doses of mRNA vaccine (or 2 doses plus a documented history of COVID) last dose being administered at least 91 days before day 0 will be included. Individuals recruited in Turkey which received a primary vaccination regimen using a combination of Coronavac and Comirnaty will be allowed to be included. A maximum of 50% of Individuals with history of COVID-19 disease will be allowed to be included if diagnosed at least 91 days prior, passed 30 days from hospital discharge prior to inclusion and provided they are no suffering from long covid (Post-acute COVID-19 syndrome). All participants will receive a single dose of PHH-1V on Day 0 and will be observed for 15 minutes, except for those participants reporting previous mild allergy reactions to vaccination will be observed for 30 minutes.

All participants will be provided with a paper diary on Day 0 to record solicited local and systemic reactions after vaccination through Day 7. Unsolicited adverse events will be reported through Day 28. SAEs, AESI and MAAE will be reported during all the study.

On-site follow-up visits will be performed on Days 14, 91, 182 and 365.

03

Conditions studied

  • SARS CoV 2 Infection

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 Male, female or transgender, ≥ 18 years old at Day 0.
  • 2 Provide inform consent form
  • 3 Participant who has: 3 doses of mRNA vaccines / 2 doses of mRNA vaccines and previous COVID-19 infection / 2 doses of Coronavac and 1 Comirnaty, or, 1 Coronavac and 2 Comirnaty
  • 4 Participant who has: infection with \<400 / Primary antibody deficiency disorders / Kidney disease on dialysis / Kidney transplant at least >1 year / Auto Immune Disease (AID) in treatment with rituximab
  • 5 For a female of , to have a negative pregnancy test at Day 0
  • Use of any of these :
  • Female: hormonal contraception, intrauterine device, vasectomized partner, sexual abstinence, condom.
  • Male: Vasectomized participant, sexual abstinence, condom.

Exclusion criteria

Exclusion Criteria:

  • 6 History of anaphylaxis to any prior vaccine
  • 7 Participants has received or plans to receive , other not live vaccines, or Vaxzevria or Janssen vaccines.
  • 8 Pregnant or breast-feeding at Day 0.
  • 9 A confirmed COVID-19 diagnose \<90 days prior to vaccination day 0.
  • 10 A acute illness or fever at screening or 48h before day 0.
  • 11 Participant had a surgery requiring hospitalisation and has not received the hospital discharge.
  • 12 Participant has an ongoing severe and non-stable psychiatric condition
  • 13 Participant has a problematic or risky use of substances including alcohol
  • 14 Participant has a bleeding disorder that contraindicates intramuscular injection
  • 15 Participant suffering from post-acute COVID-19 syndrome / long COVID
  • 16 Participant received any immunotherapy to prevent/treat COVID-19 in the last 90 days
  • 17 Participant is already participating in another research involving drug, biologics or device
  • 18 Participant has donated ≥450 ml of blood products within 12 weeks before screening
  • 19 Participant has any medical condition and/or finding that in the investigator opinion might increase participant risk, interfere with the study or impair interpretation of study data.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Experimental: COVID-19 Vaccine HIPRA 40 mcg/dose

    Intramuscular injection of HIPRA's COVID-19 vaccine, consisting of 40 mcg/dose.

    Biological: PHH-1V

Interventions

06

What researchers measure

Primary outcomes

  1. Immunogenicity against Omicron, Beta, Delta at Day 0 and Day 14

    Changes in neutralising antibodies measured by pseudovirus (or live virus for the HIV cohort\*) neutralization against Omicron, Beta and Delta any other relevant Variants of Concern (VOC) in the epidemiologic moment, at Baseline and at Day 14 after administration of HIPRA's vaccine (PHH-1V).

    Time frame: Day 0 and Day 14

Secondary outcomes

  1. Immunogenicity against Omicron, Beta, Delta at Day 91, Day 182 and Day 365

    1\. To determine and compare the changes of the immunogenicity measured by pseudovirus (or live virus for the HIV cohort) neutralization against Omicron, Beta and Delta and any other relevant Variants of Concern (VOC) in the epidemiologic moment at Days, 91, 182 and 365, after administration of HIPRA's vaccine (PHH-1V).

    Time frame: Day 91, Day 182 and Day 365

  2. Total antibodies

    To evaluate the immunogenicity measured by means of total antibody against Receptor Binding Domain of the Spike protein of SARS-CoV-2 quantification, measured by an electrochemiluminescence immunoassay (ECLIA) at Baseline and at Days 14, 91, 182 and 365 after administration of HIPRA's vaccine (PHH-1V).

    Time frame: Day 0, Day 14, Day 91, Day 182, Day 365

  3. Safety and tolerability of the booster vaccine

    To assess the safety and tolerability of PHH-1V as an additional dose in adult individuals with pre-existing immunosuppressive conditions

    Time frame: Day 0, Day 14, Day 91, Day 182, Day 365

Other outcomes

  1. Number of SARS-CoV-2 infections

    Number of participants with SARS-CoV-2 infections ≥14 days after PHH-1V administration.

    Time frame: Day 0, Day 14, Day 91, Day 182, Day 365

  2. Number of SARS-CoV-2 severe infections (Severe cases are considered as any episode of COVID-19 requiring ≥ 24hrs of hospitalization.)

    Number of COVID-19 severe infections ≥14 days after PHH-1V administration.

    Time frame: Day 0, Day 14, Day 91, Day 182, Day 365

  3. Celular immunity

    Antibody IgG subclasses titre usage and avidity of humoral immunity at Baseline and Days 14, 91, 182 and 365.

    Time frame: Day 0, Day 14, Day 91, Day 182, Day 365

  4. T-cell cellullar immunity

    T-cell mediated phenotype polyclonality with potential cross-reactivity capacity and gene-expression profiles against the SARS-CoV-2 Spike \& RBD proteins at Baseline and at Days 14, 91, 182 and 365 in a subset of 50% of participants.

    Time frame: Day 0, Day 14, Day 91, Day 182, Day 365

07

Study locations

6 sites
  • Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital Clínic de Barcelona
    Barcelona, Barcelona 08036, Spain
  • Hospital Josep Trueta
    Girona, Girona 17001, Spain
  • Hacettepe University Medical Faculty Hospitals
    Ankara, Ankara 06230, Turkey (Türkiye)
  • Ankara University Medical Faculty Hospitals
    Ankara, Ankara 06620, Turkey (Türkiye)
  • Koc University Hospital
    Istanbul, Istanbul 34010, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jan 2024, 19 months.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 19 months is above that.

Counting every sponsor, half of 169 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jul 2023 → Jan 2024 and completion Dec 2023 → Jan 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2022
First posted
Mar 31, 2022
StartActual
May 12, 2022
Primary completionActual
Jan 9, 2024was Jul 2023
CompletionActual
Jan 9, 2024was Dec 2023
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 29, 2023→Jan 9, 2024
Nov 17, 2026
Study completion
Dec 1, 2023→Jan 9, 2024
Nov 17, 2026
Enrollment
241→240
Nov 17, 2026
Eligibility
4 inclusion criteria edited, 1 added, 9 removed; 14 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • Edited1 Male, female or transgender, ≥ 18 years old at Day 0.
  • Edited2 Provide inform consent form
  • RemovedParticipant who has:
  • Removed3 doses of mRNA vaccines
  • Removed2 doses of mRNA vaccines and previous COVID-19 infection
  • Edited3 Participant who has: 3 doses of mRNA vaccines / 2 doses of mRNA vaccines and previous COVID-19 infection / 2 doses of Coronavac and 1 Comirnaty, or, 1 Coronavac and 2 Comirnaty
  • RemovedParticipant who has:
  • RemovedHIV infection with CD4 Tcells counts <400
  • RemovedPrimary antibody deficiency disorders
  • RemovedKidney disease on dialysis
  • RemovedKidney transplant at least >1 year
  • RemovedAuto Immune Disease (AID) in treatment with rituximab
  • Added4 Participant who has: HIV infection with CD4 Tcells counts <400 / Primary antibody deficiency disorders / Kidney disease on dialysis / Kidney transplant at least >1 year / Auto Immune Disease (AID) in treatment with rituximab
  • Edited5 For a female of childbearing potential, to have a negative pregnancy test at Day 0
Exclusion criteria
  • Edited6 History of anaphylaxis to any prior vaccine
  • Edited7 Participants has received or plans to receive live attenuated vaccines, other not live vaccines, or Vaxzevria or Janssen vaccines.
  • Edited8 Pregnant or breast-feeding at Day 0.
  • Edited9 A confirmed COVID-19 diagnose <90 days prior to vaccination day 0.
  • Edited10 A clinically significant acute illness or fever at screening or 48h before day 0.
  • Edited11 Participant had a surgery requiring hospitalisation and has not received the hospital discharge.
  • Edited12 Participant has an ongoing severe and non-stable psychiatric condition
  • Edited13 Participant has a problematic or risky use of substances including alcohol
  • Edited14 Participant has a bleeding disorder that contraindicates intramuscular injection
  • Edited15 Participant suffering from post-acute COVID-19 syndrome / long COVID
  • Edited16 Participant received any immunotherapy to prevent/treat COVID-19 in the last 90 days
  • Edited17 Participant is already participating in another research involving drug, biologics or device
  • Edited18 Participant has donated ≥450 ml of blood products within 12 weeks before screening
  • Edited19 Participant has any medical condition and/or finding that in the investigator opinion might increase participant risk, interfere with the study or impair interpretation of study data.
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Jul 29, 2023→Jan 9, 2024
    Study completion Dec 1, 2023→Jan 9, 2024
    Enrollment 241→240
    Eligibility 4 inclusion criteria edited, 1 added, 9 removed; 14 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • Edited1 Male, female or transgender, ≥ 18 years old at Day 0.
    • Edited2 Provide inform consent form
    • RemovedParticipant who has:
    • Removed3 doses of mRNA vaccines
    • Removed2 doses of mRNA vaccines and previous COVID-19 infection
    • Edited3 Participant who has: 3 doses of mRNA vaccines / 2 doses of mRNA vaccines and previous COVID-19 infection / 2 doses of Coronavac and 1 Comirnaty, or, 1 Coronavac and 2 Comirnaty
    • RemovedParticipant who has:
    • RemovedHIV infection with CD4 Tcells counts <400
    • RemovedPrimary antibody deficiency disorders
    • RemovedKidney disease on dialysis
    • RemovedKidney transplant at least >1 year
    • RemovedAuto Immune Disease (AID) in treatment with rituximab
    • Added4 Participant who has: HIV infection with CD4 Tcells counts <400 / Primary antibody deficiency disorders / Kidney disease on dialysis / Kidney transplant at least >1 year / Auto Immune Disease (AID) in treatment with rituximab
    • Edited5 For a female of childbearing potential, to have a negative pregnancy test at Day 0
    Exclusion criteria
    • Edited6 History of anaphylaxis to any prior vaccine
    • Edited7 Participants has received or plans to receive live attenuated vaccines, other not live vaccines, or Vaxzevria or Janssen vaccines.
    • Edited8 Pregnant or breast-feeding at Day 0.
    • Edited9 A confirmed COVID-19 diagnose <90 days prior to vaccination day 0.
    • Edited10 A clinically significant acute illness or fever at screening or 48h before day 0.
    • Edited11 Participant had a surgery requiring hospitalisation and has not received the hospital discharge.
    • Edited12 Participant has an ongoing severe and non-stable psychiatric condition
    • Edited13 Participant has a problematic or risky use of substances including alcohol
    • Edited14 Participant has a bleeding disorder that contraindicates intramuscular injection
    • Edited15 Participant suffering from post-acute COVID-19 syndrome / long COVID
    • Edited16 Participant received any immunotherapy to prevent/treat COVID-19 in the last 90 days
    • Edited17 Participant is already participating in another research involving drug, biologics or device
    • Edited18 Participant has donated ≥450 ml of blood products within 12 weeks before screening
    • Edited19 Participant has any medical condition and/or finding that in the investigator opinion might increase participant risk, interfere with the study or impair interpretation of study data.
    + 4 other changes: verification date, oversight details, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05303402
Lead sponsor
Hipra Scientific, S.L.U
Collaborators
Veristat, Inc., Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Asphalion
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
May 12, 2022
Primary completion
Jan 9, 2024
Completion
Jan 9, 2024
Last update
Nov 17, 2026

Study contacts

Teresa Prat
study director · Hipra Scientific, S.L.U

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HIPRA COVID-19 vaccine

Start the discussion